General Information of Drug (ID: DMMB29S)

Drug Name
Orotate Drug Info
Synonyms
73-97-2; Orotic acidanion; AC1LSPNG; CHEBI:30839; CTK5D9013; DTXSID80363448; PXQPEWDEAKTCGB-UHFFFAOYSA-M; AG-G-93379; 2,4-dioxo-1H-pyrimidine-6-carboxylate; CJ-15820; 21317-EP2314295A1; 21317-EP2284172A1; 21317-EP2281559A1; 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylate; 4-Pyrimidinecarboxylicacid, 1,2,3,6-tetrahydro-2,6-dioxo-, ion(1-)
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
1492348
ChEBI ID
CHEBI:30839
CAS Number
CAS 73-97-2
TTD Drug ID
DMMB29S
VARIDT Drug ID
DR00157

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Artemisinin DMOY7W3 Malaria 1F40-1F45 Approved [3]
Leflunomide DMR8ONJ Arthritis FA20 Approved [4]
Teriflunomide DMQ2FKJ Hyperlipidaemia 5C80 Approved [5]
Atovaquone DMY4UMW Fungal infection 1F29-1F2F Approved [6]
Avastin+/-Tarceva DMA86FL Non-small-cell lung cancer 2C25.Y Phase 3 [7]
Acetate Ion DMD08RH Discovery agent N.A. Investigative [8]
B-Octylglucoside DMMO75G Discovery agent N.A. Investigative [8]
Lauryl Dimethylamine-N-Oxide DM3W2OE Discovery agent N.A. Investigative [8]
1,4-Naphthoquinone DMTCMH7 Discovery agent N.A. Investigative [7]
Dihydroorotate DM76BGZ Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lysine Nz-Carboxylic Acid DMW1YK3 Discovery agent N.A. Investigative [8]
Dihydroorotate DM76BGZ Discovery agent N.A. Investigative [8]
5-Fluoro orotate DMLSC10 Discovery agent N.A. Investigative [1]
5-bromo orotate DM0HCG6 Discovery agent N.A. Investigative [1]
N-Carbamoyl-L-Aspartate DMJ13TR Discovery agent N.A. Investigative [8]
5-iodo orotate DMDKFIO Discovery agent N.A. Investigative [1]
5-methyl orotate DMYNFIP Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 7 Drug(s)
Drug(s) Transported By Urate anion exchanger 1 (SLC22A12)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Oxypurinol DMURH4X Heart failure BD10-BD13 Phase 2/3 [10]
uric acid DMA1MKT Discovery agent N.A. Investigative [11]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Plasmodium Dihydroorotase (Malaria dho) TT09NOX A9CSR1_PLAFA Inhibitor [1]
Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) TT3PQ2Y PYRD_PLAF7 Inhibitor [1]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Urate anion exchanger 1 (SLC22A12) DT2WLAD S22AC_HUMAN Substrate [2]

References

1 Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301.
2 Human urate transporter 1 (hURAT1) mediates the transport of orotate. J Physiol Sci. 2011 May;61(3):253-7.
3 The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
4 Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases. Eur J Biochem. 1999 Dec;266(3):1184-91.
5 Expression and characterization of E. coli-produced soluble, functional human dihydroorotate dehydrogenase: a potential target for immunosuppression. J Mol Microbiol Biotechnol. 1999 Aug;1(1):183-8.
6 Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein Sci. 2004 Apr;13(4):1031-42.
7 Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76.
8 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9 Structure-activity relationships of pyrimidines as dihydroorotate dehydrogenase inhibitors. Biochem Pharmacol. 1988 Oct 15;37(20):3807-16.
10 Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. Drug Metab Dispos. 2005 Dec;33(12):1791-5.
11 Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther. 2007 Jan;320(1):211-7.